
Oncology Treatment Pathway Optimizer
Generate evidence-based oncology treatment pathways with staging and prognostic integration
What You Can Do
You can synthesize complex patient data—histopathology, molecular profiling, imaging findings, and comorbidities—into structured treatment recommendations aligned with NCCN, ESMO, and ASCO guidelines. The skill accelerates the pathway from diagnosis to actionable decisions by organizing multifactorial information, stratifying risk, flagging guideline-discordant scenarios, and integrating emerging evidence like clinical trial eligibility and novel biomarkers into conventional staging systems.
Features
Correlate TNM staging, molecular markers, and genomic profiling with guideline-recommended pathways
Calculate risk scores and prognosis based on tumor characteristics, performance status, and comorbidities
Structure recommendations requiring input from surgery, radiation, medical oncology, and supportive care
Cross-reference NCCN, ESMO, and ASCO recommendations with current published evidence
Identify trial eligibility criteria and match patient characteristics to active studies
Evaluate outcomes and trade-offs across surgery, chemotherapy, radiation, immunotherapy, and targeted therapy options
Generate rationale for pathway deviations when institutional protocols or patient factors diverge from standard recommendations
Assess how performance status, organ function, and concurrent conditions modify standard treatment algorithms
Example Output
Example 1: Stage III Non-Small Cell Lung Cancer
Patient Summary: 62-year-old, ECOG 1, stage IIIA adenocarcinoma, PD-L1 50%, EGFR wild-type
Recommended Pathway:
- Concurrent chemoradiotherapy (cisplatin/pemetrexed + 60 Gy) followed by consolidation durvalumab
- Rationale: PACIFIC trial supports immunotherapy post-chemoradiation; PD-L1 50% favorable for consolidation
- Comorbidity Note: ECOG 1 tolerable; baseline pulmonary function required given thoracic radiation
- Trial Eligibility: Consider enrollment in ongoing PD-L1 biomarker-driven trials
Example 2: Metastatic Colorectal Cancer with MSI-H
Patient Summary: 54-year-old, ECOG 0, metastatic CRC, microsatellite instability-high, BRAF wild-type
Recommended Pathway:
- First-line: pembrolizumab monotherapy (preferred per KEYNOTE-177) OR nivolumab + ipilimumab
- Rationale: MSI-H status predicts durable response to checkpoint inhibition; avoid cytotoxic chemotherapy as first-line
- Prognostic Note: MSI-H status favorable; consider minimal residual disease monitoring
- Alternative if comorbidities preclude immunotherapy: FOLFOXIRI + bevacizumab
Example 3: Early-Stage Breast Cancer (HER2+)
Pathway Decision Tree:
- Hormone Receptor Status: ER/PR negative → omit endocrine therapy
- HER2 Amplification: Use trastuzumab-based regimen (12 months)
- Lymph Node Involvement: 1-3 nodes → consider de-escalation (HER2-directed monotherapy without chemotherapy if low recurrence risk)
- Germline Testing: BRCA1/2 mutation carrier → discuss taxane sensitivity and surveillance implications
What's Included
- SKILL.md: Complete instruction set for pathway analysis and recommendation generation
- Staging Reference Template: TNM staging correlations and prognostic factor integration framework
- Guideline Decision Algorithm: NCCN/ESMO/ASCO pathway flowcharts for major cancer types (lung, colorectal, breast, prostate, lymphoma, pancreatic)
- Risk Stratification Checklist: Prognostic variables, biomarker interpretation, and comorbidity weighting schema
- Clinical Trial Matching Framework: Inclusion/exclusion criteria cross-reference and trial eligibility assessment workflow
- Treatment Modality Comparison Matrix: Outcomes, toxicity profiles, and decision rationale template across surgery, chemotherapy, radiation, immunotherapy, and targeted therapy
Who It's For
- Oncologists — designing evidence-based treatment plans and preparing tumor board presentations
- Medical Oncology Fellows — learning systematic pathway selection and guideline integration
- Tumor Board Coordinators — structuring multidisciplinary case presentations with clear decision rationale
- Radiation Oncologists — integrating radiation recommendations into multimodal treatment pathways
- Surgical Oncologists — evaluating surgical candidacy within multimodal treatment strategies
Best For
- Initial treatment recommendation development post-staging
- Molecular and genomic result integration into pathway selection
- Tumor board case preparation with risk stratification
- Clinical trial eligibility screening and matching
- Guideline-concordant vs. discordant pathway documentation and justification
- Comorbidity-adjusted treatment algorithm modification
- Second opinion case analysis and evidence synthesis







